Toxicity Testing For Topical Drugs, Sunscreens Included, On Tap In US FDA Workshop
This article was originally published in The Rose Sheet
Executive Summary
While FDA does not identify specific product types on the agenda for its public workshop on approaches in skin toxicity testing for topical drug products, advocacy and trade groups anticipate sunscreen ingredient testing could be among the discussion topics. Product expansions have been stifled by regulatory concerns, drawing particular attention from the public health community.
You may also be interested in...
FDA Shopping For 3D Tissue Bioprinter, Cosmetic Contamination Testing Services
Recent procurement activities show an agency increasingly focused on cosmetics’ safety vis-a-vis microbial threats and, in the case of talc-containing products, asbestos. Meanwhile, FDA seeks a 3D bioprinter to use in organ toxicity studies as an alternative to traditional animal models.
US FDA's Sunscreen Progress Gets Dim Review From Congressional Appropriators
House and Senate appropriators' take note that US FDA has not approved an additional OTC sunscreen ingredient since the 2014 passage of the Sunscreen Innovation Act.
Appropriators Agree On Boosting FDA's Supplement Sector Work, Not On Funding
House and Senate appropriation bills state markedly different funding levels for FDA's spending on research into supplement and food products by its Center for Food Safety and Applied Nutrition and on enforcement work in the field by the Office of Regulatory Affairs. Appropriators are more aligned, though, in requests to FDA about its oversight of dietary supplement manufacturing and marketing.